[Calmette-Guerin bacillus in the prophylaxis of superficial bladder tumors. Our experience and our doubts]. / Bacilo de Calmette-Guerin en la profilaxis de los tumores superficiales de vejiga. Nuestra experiencia y nuestras dudas.

OBJECTIVE: This study was conducted to determine the efficacy of our BCG dose and schedule for prophylactic therapy in superficial bladder tumors. METHODS: Following complete TUR, 81 mg intravesical BCG were administered weekly for six weeks and for nightly another six times. The patients were evaluated every three months by cytology, cystoscopy and routine analysis. RESULTS: 21/25 patients completed the treatment. At 15.5 months median follow-up, 18/21 (85.7%) were disease-free, 2/21 (9.5%) had recurrence and 1/21 (4.7%) showed disease progression. CONCLUSIONS: BCG is the most effective prophylactic therapy for superficial bladder tumors currently available. The ideal dose, treatment schedule and its mechanism of action are as yet unknown.

[The ovarian vein syndrome. Its treatment by percutaneous embolization and a review of the same]. / Síndrome de la vena ovárica. Tratamiento por emoblización percutánea y revisión del mismo.

Since Clark first described the ovarian vein syndrome in 1964, there has been much controversy over its existence. We report two cases of ovarian vein syndrome whose presenting feature was lumbar pain. Following treatment by percutaneous coil embolization of the corresponding ovarian vein, the symptoms rapidly improved and the patients are asymptomatic at 8 and 21 months follow up. We underscore the importance of symptomatic relief over the radiologic findings. The most important aspects and controversies of this syndrome are briefly reviewed.